June 5 (Reuters) - Nektar Therapeutics:
* Presented new findings from two phase 1 clinical studies of NKTR-214, nektar's lead immuno-oncology candidate
* Nektar therapeutics - "NKTR-214 monotherapy demonstrated a favorable safety profile with no immune-related adverse events"
* Data from blood and tumor samples show that NKTR-214 increases immune cells in blood and tumor microenvironment
* All dose cohorts of NKTR-214 and nivolumab demonstrate a favorable safety profile and are well-tolerated Source text for Eikon: Further company coverage: